TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34393512

Group type: EXPERIMENTAL
Intervention: EORTC QLQ-C30 and QLQ-LC29 questionnaires
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Hornheide Screening Instrument (HSI)
Number of subjects: 81

Group type: COMPARATOR
Intervention: EORTC questionnaires as screening instrument
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: HSI
Number of subjects: 81
Study: 34393800

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment (doses not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no corticosteroid treatment)
Number of subjects: 0
Study: 34394195

Group type: EXPERIMENTAL
Intervention: DNA methylation analysis of A-FAT and GF-FAT using BeadChip Methylation Array.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DNA methylation sites in adipose tissue.
Number of subjects: 0
Study: 34394782

Group type: EXPERIMENTAL
Intervention: Tiotropium/olodaterol 5/5 µg fixed dose combination for 6 weeks
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Tiotropium/olodaterol treatment
Number of subjects: 94
Study: 34394947

Group type: EXPERIMENTAL
Intervention: Presence of perioperative complications
Number of subjects: 912

Group type: COMPARATOR
Intervention: Absence of perioperative complications
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Perioperative complications
Number of subjects: 912
Study: 34395277

Group type: EXPERIMENTAL
Intervention: Preoperative systemic treatment
Number of subjects: 1067

Group type: COMPARATOR
Intervention: Upfront surgery
Number of subjects: 1067
Study: 34395457

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34395487

Group type: EXPERIMENTAL
Intervention: Daytime dry fasting
Number of subjects: 0
Study: 34395560

Group type: EXPERIMENTAL
Intervention: Subcutaneous Implantable Cardioverter-Defibrillator (S-ICD) implantation
Number of subjects: 0
Study: 34395684

Group type: EXPERIMENTAL
Intervention: Early ACL repair (augmented or nonaugmented) plus rehabilitation
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Single-leg hop limb symmetry index <90% at 4 years
Number of subjects: 172

Group type: COMPARATOR
Intervention: Delayed ACL reconstruction (ACLR)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Rehabilitation alone
Number of subjects: 172

Group type: COMPARATOR
Intervention: Quadriceps and hamstring strength, flexion and extension deficit
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Reduced self-reported knee function and single-leg hop performance at 4 years
Number of subjects: 172
Study: 34396154

Group type: EXPERIMENTAL
Intervention: First COVID-19 vaccination
Number of subjects: 921

Group type: EXPERIMENTAL
Intervention: Second COVID-19 vaccination
Number of subjects: 921

Group type: EXPERIMENTAL
Intervention: Immunosuppressive drugs
Number of subjects: 921

Group type: COMPARATOR
Intervention: Control group (healthy individuals)
Number of subjects: 921
Study: 34396157

Group type: EXPERIMENTAL
Intervention: Trastuzumab with ACE inhibitors and/or beta-blockers
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: ACE inhibitors and/or beta-blockers
Number of subjects: 20
Study: 34396175

Group type: EXPERIMENTAL
Intervention: Cancer patients undergoing PCI
Number of subjects: 1368
Study: 34396210

Group type: EXPERIMENTAL
Intervention: GnRH antagonist degarelix
Number of subjects: 900

Group type: COMPARATOR
Intervention: GnRH agonist leuprolide
Number of subjects: 900
Study: 34396246

Group type: EXPERIMENTAL
Intervention: ezetimibe 10 mg
Number of subjects: 17708

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 17708
Study: 34396283

Group type: EXPERIMENTAL
Intervention: Variants in cardiac injury pathway genes
Number of subjects: 289

Group type: COMPARATOR
Intervention: Control patients (no specific intervention mentioned)
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Anthracycline exposure
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Prediction model for delayed anthracycline cardiotoxicity
Number of subjects: 289
Study: 34397042

Group type: EXPERIMENTAL
Intervention: Consecutive therapy consisting of esomeprazole 40 mg or rabeprazole 20 mg twice daily, amoxicillin 1,000 mg twice daily, tetracycline 500 mg 4 times daily, and furazolidone 100 mg 3 times daily for the first 7 days, followed by colloidal bismuth pectin 200 mg twice daily for another 7 days.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Consecutive therapy including amoxicillin, tetracycline, and furazolidone.
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Resistance rates to antibiotics in patients with available antimicrobial susceptibility testing results (51 patients).
Number of subjects: 65
Study: 34397100

Group type: EXPERIMENTAL
Intervention: Oral chloral hydrate
Number of subjects: 2922

Group type: COMPARATOR
Intervention: Chloral hydrate
Number of subjects: 2922
Study: 34397263

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 34397515

Group type: EXPERIMENTAL
Intervention: Primary DD surgery (including percutaneous needle fasciotomy, limited fasciectomy, or dermofasciectomy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary DD surgery
Number of subjects: 0
Study: 34397539

Group type: EXPERIMENTAL
Intervention: Tafamidis (Vyndaqel and Vyndamax)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inotersen and patisiran
Number of subjects: 0

Group type: COMPARATOR
Intervention: Symptomatic management and traditional therapies for congestive heart failure
Number of subjects: 0
Study: 34397699

Group type: EXPERIMENTAL
Intervention: Various treatment regimens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disease-related outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physiological and molecular modifications
Number of subjects: 0
Study: 34397707

Group type: EXPERIMENTAL
Intervention: Control of glycosylated hemoglobin (HbA1c) < 7%
Number of subjects: 20412

Group type: EXPERIMENTAL
Intervention: Control of blood pressure < 130/80 mm Hg
Number of subjects: 20412

Group type: EXPERIMENTAL
Intervention: Control of low-density lipoprotein cholesterol (LDL-C) < 2.6 mmol/l
Number of subjects: 20412

Group type: EXPERIMENTAL
Intervention: Achievement of all 3 targets (HbA1c, blood pressure, LDL-C)
Number of subjects: 20412
Study: 34397713

Group type: EXPERIMENTAL
Intervention: Baricitinib for 12 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Baricitinib for 24 weeks
Number of subjects: 20
Study: 34397719

Group type: EXPERIMENTAL
Intervention: Triptorelin (Diphereline, 3.75 mg intramuscular injection once every 28 days for up to 24 weeks) - Group A (1-3 injections)
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Triptorelin (Diphereline, 3.75 mg intramuscular injection once every 28 days for up to 24 weeks) - Group B (4-6 injections)
Number of subjects: 384
Study: 34397987

Group type: EXPERIMENTAL
Intervention: empagliflozin (10 mg once daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: sitagliptin (100 mg once daily)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: empagliflozin
Number of subjects: 100

Group type: COMPARATOR
Intervention: sitagliptin
Number of subjects: 100

Group type: COMPARATOR
Intervention: empagliflozin vs. sitagliptin
Number of subjects: 100
Study: 34398056

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine (0.5 mg/kg)
Number of subjects: 49
Study: 34398061

Group type: EXPERIMENTAL
Intervention: High step (16,048 ± 725 steps per day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low step (4767 ± 377 steps per day)
Number of subjects: 16
Study: 34398099

Group type: EXPERIMENTAL
Intervention: Topical and parenteral antimicrobial therapy without wound débridement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic antimicrobial therapy in combination with wound débridement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional and emerging antibiofilm therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Commercial products to manage wound biofilm infection
Number of subjects: 0
Study: 34398238

Group type: EXPERIMENTAL
Intervention: Interleukin-7 (IL-7) administration to ICL patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 34398492

Group type: EXPERIMENTAL
Intervention: FibroTest
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: NashTest-2
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: SteatoTest-2
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Ballooning
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Lobular inflammation
Number of subjects: 272
Study: 34398557

Group type: EXPERIMENTAL
Intervention: Novel drugs targeting pathways involved in B-cell receptor signaling
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Agents that inhibit targets of the leukemia microenvironment
Number of subjects: 0
Study: 34398588

Group type: EXPERIMENTAL
Intervention: Post-Surgical Stereotactic Radiotherapy (SRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgically Targeted Radiation Therapy (STaRT) with GammaTile
Number of subjects: 0
Study: 34398631

Group type: EXPERIMENTAL
Intervention: Lower perceived social support from significant others and friends
Number of subjects: 63

Group type: COMPARATOR
Intervention: Perceived social support from family
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Perceived social support from friends
Number of subjects: 63
Study: 34398787

Group type: EXPERIMENTAL
Intervention: TOGETHERCare mobile app
Number of subjects: 7
Study: 34398907

Group type: EXPERIMENTAL
Intervention: Fluoroquinolones (FQ)
Number of subjects: 51898

Group type: COMPARATOR
Intervention: Negative control exposures (NCE)
Number of subjects: 51898

Group type: EXPERIMENTAL
Intervention: Pre-exposure period
Number of subjects: 51898
Study: 34398971

Group type: EXPERIMENTAL
Intervention: Chidamide-cladribine-gemcitabine-busulfan (ChiCGB) combination as conditioning therapy after transplantation with autologous peripheral stem cells.
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Chidamide-cladribine-gemcitabine-busulfan (ChiCGB) combination as conditioning therapy.
Number of subjects: 105
Study: 34399137

Group type: EXPERIMENTAL
Intervention: Cannabis smoking
Number of subjects: 14
Study: 34399432

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (OACs)
Number of subjects: 11972

Group type: COMPARATOR
Intervention: No AF (control group)
Number of subjects: 11972
Study: 34399717

Group type: EXPERIMENTAL
Intervention: Sedentary behaviour (measured using ActivPal®)
Number of subjects: 257
Study: 34399731

Group type: EXPERIMENTAL
Intervention: Routine health checks conducted by school doctors
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Children classified as needing a health check
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Study questionnaires assessing need for health check
Number of subjects: 1341
Study: 34399736

Group type: EXPERIMENTAL
Intervention: PrEP provision
Number of subjects: 2567
Study: 34399737

Group type: EXPERIMENTAL
Intervention: Dignity Therapy (DT) intervention
Number of subjects: 37
Study: 34399811

Group type: EXPERIMENTAL
Intervention: Headache
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Nausea/vomiting
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Neck pain
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Cardiac arrest
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Persisting unconsciousness
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Inability to stand up
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Speech difficulty
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Sweating
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Headache and nausea/vomiting combination
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Syncope
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Nausea/vomiting (in conscious patients)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Headache (in conscious patients)
Number of subjects: 224
Study: 34399830

Group type: COMPARATOR
Intervention: Acute-stage monocytes (n=75)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Recovery-stage monocytes (n=56)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Multi-scale model
Number of subjects: 75
Study: 34399856

Group type: EXPERIMENTAL
Intervention: Peri-conception nutrition and exercise intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study: 34400137

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 448

Group type: COMPARATOR
Intervention: Hysterectomy and lymph node staging without adjuvant therapy
Number of subjects: 448

Group type: COMPARATOR
Intervention: Hysterectomy (plus bilateral salpingo-oophorectomy) alone
Number of subjects: 448
Study: 34400140

Group type: EXPERIMENTAL
Intervention: Abnormal cardiovascular resonance imaging (CMR) findings
Number of subjects: 58

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Cardiac troponin T and N-terminal pro-B-type natriuretic peptide concentrations on admission
Number of subjects: 58
Study: 34400337

Group type: EXPERIMENTAL
Intervention: Garcinia cambogia alone
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Garcinia cambogia with green tea
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Garcinia cambogia containing HDS
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control groups (HDS containing green tea without G cambogia and other HDS)
Number of subjects: 22
Study: 34400362

Group type: EXPERIMENTAL
Intervention: Digital health intervention (Nourish) including skills training, self-monitoring, personalized feedback, and responsive coaching.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Attention control arm (not specified in detail).
Number of subjects: 300
Study: 34400453

Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (cTBS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cTBS
Number of subjects: 0
Study: 34400454

Group type: EXPERIMENTAL
Intervention: Preventive strategy of fluid removal initiated systematically when fluid balance or weight change is positive and patients are clinically stable.
Number of subjects: 410

Group type: COMPARATOR
Intervention: Curative strategy of fluid removal initiated only in case of weaning failure documented as of cardiac origin.
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Preventive strategy
Number of subjects: 410

Group type: COMPARATOR
Intervention: Curative strategy
Number of subjects: 410
Study: 34400568

Group type: EXPERIMENTAL
Intervention: Adult Assisting Hand Assessment Stroke (Ad-AHA)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Fugl-Meyer Assessment (FMA)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: FMA-SAFE score
Number of subjects: 89
Study: 34400574

Group type: EXPERIMENTAL
Intervention: Widespread pain
Number of subjects: 2464

Group type: COMPARATOR
Intervention: No widespread pain (Control)
Number of subjects: 2464
Study: 34400910

Group type: EXPERIMENTAL
Intervention: RIFA quantification method
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: RIFA-correlated genes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Differentially expressed genes analysis
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Single-cell RNA sequencing analysis
Number of subjects: 20
Study: 34401374

Group type: EXPERIMENTAL
Intervention: Online cognitive behavior therapy (CBT) targeting avoidance behavior, duration: 8 weeks, with therapist support
Number of subjects: 30
Study: 34401394

Group type: EXPERIMENTAL
Intervention: Standard feedback
Number of subjects: 1074

Group type: EXPERIMENTAL
Intervention: Tailored feedback
Number of subjects: 1074

Group type: COMPARATOR
Intervention: No feedback (control arm)
Number of subjects: 1074
Study: 34401600

Group type: EXPERIMENTAL
Intervention: BLZ-100 (tozuleristide) administered intravenously at doses of 1, 3, 6, 12, and 18 mg, 2 days before tumor excision.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: BLZ-100 (tozuleristide) administered intravenously at intermediate doses (3-12 mg).
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: BLZ-100 (tozuleristide) administered intravenously.
Number of subjects: 21
Study: 34401686

Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC) initiated <24 hours after admission
Number of subjects: 279

Group type: COMPARATOR
Intervention: Standard care including KMC once stable at >24 hours after admission
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: KMC initiated <24 hours after admission
Number of subjects: 279
Study: 34401690

Group type: EXPERIMENTAL
Intervention: Alcohol intervention via nasogastric tube over 30 min
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Alcohol intervention
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Alcohol intoxication
Number of subjects: 39
Study: 34401724

Group type: EXPERIMENTAL
Intervention: Integrated digital health system tools including an automated CKD patient registry, risk prediction algorithm, electronic patient-facing values clarification tool, tracking application, and EHR workflow.
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: Values clarification tool
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: Tracking application used by nurse case managers
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: Documentation of preferred kidney replacement modality
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: Digital health system tools
Number of subjects: 1032
Study: 34401861

Group type: EXPERIMENTAL
Intervention: Atorvastatin-based lipid therapies and lifestyle intervention for 2 years
Number of subjects: 217
Study: 34401888

Group type: EXPERIMENTAL
Intervention: mRNA-1273 vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Day 57 Spike IgG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Day 57 RBD IgG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Day 57 cID50 neutralization levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Day 57 cID80 neutralization levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cID50 neutralization titers <2.42, 100, or 1000
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Day 29 cID50 titer
Number of subjects: 0
Study: 34402466

Group type: EXPERIMENTAL
Intervention: High-dose adalimumab (40 mg weekly, 80 mg every other week or greater)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Standard adalimumab (40 mg every other week)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 79
Study: 34402795

Group type: EXPERIMENTAL
Intervention: Telehealth-based exercise training (20 weeks of moderate-intensity aerobic training, 5 days a week)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Telehealth-based exercise training
Number of subjects: 3
Study: 34402876

Group type: EXPERIMENTAL
Intervention: Standardized biannual five-hour examination and annual follow-up interviews
Number of subjects: 3289
Study: 34402932

Group type: EXPERIMENTAL
Intervention: Aerobic training (10 weeks supervised)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Baseline metabolic assessments
Number of subjects: 23
Study: 34403125

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for chronic pain and shared decision-making for prescription opioid dose reduction
Number of subjects: 20
Study: 34403803

Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 0
Study: 34404257

Group type: EXPERIMENTAL
Intervention: Onabotulinum toxin-A
Number of subjects: 32
Study: 34404358

Group type: EXPERIMENTAL
Intervention: Curcumin 1500 mg by mouth twice daily for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34404361

Group type: EXPERIMENTAL
Intervention: Morbid obesity
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Age increase
Number of subjects: 202
Study: 34404378

Group type: EXPERIMENTAL
Intervention: Custom questionnaire
Number of subjects: 50
Study: 34404454

Group type: EXPERIMENTAL
Intervention: LEAPS intervention (youth-led ECCE program)
Number of subjects: 1089

Group type: COMPARATOR
Intervention: Non-randomized youth participant open cohorts
Number of subjects: 1089

Group type: COMPARATOR
Intervention: LEAPS students (non-randomized school cohort)
Number of subjects: 1089

Group type: COMPARATOR
Intervention: Implementation evaluation
Number of subjects: 1089

Group type: COMPARATOR
Intervention: Cost evaluation
Number of subjects: 1089
Study: 34404458

Group type: EXPERIMENTAL
Intervention: Explainable Boosting Machine model for prediction of ICU outcomes
Number of subjects: 1039

Group type: EXPERIMENTAL
Intervention: Explainable Boosting Machine model
Number of subjects: 1039
Study: 34404463

Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg subcutaneously at baseline, weeks 1, 2, and 3, and every 4 weeks from week 4, combined with a 26-week prednisolone taper regimen.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo subcutaneously at baseline, weeks 1, 2, and 3, and every 4 weeks from week 4, combined with a 26-week prednisolone taper regimen.
Number of subjects: 50
Study: 34404623

Group type: EXPERIMENTAL
Intervention: Selinexor with supportive care
Number of subjects: 28
Study: 34404699

Group type: EXPERIMENTAL
Intervention: Common exercise programme with individualised progression criterion based on neuromuscular capacity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current best practice exercise programme for lower limb tendinopathies
Number of subjects: 0
Study: 34404711

Group type: EXPERIMENTAL
Intervention: Acute kidney replacement therapy (KRT)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Delirium assessment using the Confusion Assessment Method-ICU (CAM-ICU)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Driving safety, adverse events, and medication adherence assessment
Number of subjects: 108
Study: 34404895

Group type: EXPERIMENTAL
Intervention: mHealth (29 studies, 574,649 participants)
Number of subjects: 596128

Group type: EXPERIMENTAL
Intervention: electronic health records (13 studies, 4534 participants)
Number of subjects: 596128

Group type: EXPERIMENTAL
Intervention: telemedicine (4 studies, 465 participants)
Number of subjects: 596128

Group type: EXPERIMENTAL
Intervention: cloud-based application (2 studies, 2382 participants)
Number of subjects: 596128

Group type: EXPERIMENTAL
Intervention: information communication technology (3 studies, 681 participants)
Number of subjects: 596128

Group type: EXPERIMENTAL
Intervention: artificial intelligence (1 study, 13,417 participants)
Number of subjects: 596128
Study: 34404907

Group type: EXPERIMENTAL
Intervention: Glucose infusion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Water infusion
Number of subjects: 50